Dosimetric effect of CT contrast agent in CyberKnife treatment plans
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hee Jung | - |
dc.contributor.author | Chang, Ah Ram | - |
dc.contributor.author | Park, Yang-Kyun | - |
dc.contributor.author | Ye, Sung-Joon | - |
dc.date.accessioned | 2021-08-12T00:45:13Z | - |
dc.date.available | 2021-08-12T00:45:13Z | - |
dc.date.issued | 2013-10-18 | - |
dc.identifier.issn | 1748-717X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13282 | - |
dc.description.abstract | Background: To investigate the effect of computed tomography (CT) contrast enhancement (CE) on the 3D dose distributions of non-coplanar small field beams in the CyberKnife (CK) treatment planning system (TPS) for the stereotactic ablative radiotherapy (SABR). Methods: Twenty-two pre-CE CT treatment plans were recruited to this retrospective plan study. Their post-CE CT plans were based on the pre-CE CT plan data and calculated using the same MU and beam paths in either Ray-Tracing or Monte Carlo (MC) algorithms. The differences in the doses of the beam path and the reference point between the pre- and post-CE CT plans were compared. The minimum, maximum, and mean doses in dose-volume histograms (DVHs) of target and organs-at-risk (OARs) were also compared. Results: The dose differences between the pre-and post-CE plans in a single beam path were less than 1.05% in both calculation algorithms, with respect to the prescription dose. At the center of the target volume, it was 1.9% (maximum 6.2%) in Ray-Tracing and 1.6% (maximum 4.0%) in MC. The CA effect showed on average 1.2% difference in the OAR maximum dose (maximum 7.8% in Ray-Tracing and 7.2% in MC). In the lung cases, the CT CE resulted in a dose difference of 2.4% (from 1.0% to 6.5%) without the calculation algorithm effect (maximum 20.3%). Conclusions: The CK treatment plan using the post-CE CT generally afforded less than 2% dose differences from the pre-CE CT plan. However, it could be up to 7.8% depending on the target positions in a body and be more than 20% with the calculation algorithms. Thus, the post-CE CT in CK treatment plans should be used with careful consideration for the CA effect, target position, and calculation algorithm factors. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BioMed Central | - |
dc.title | Dosimetric effect of CT contrast agent in CyberKnife treatment plans | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/1748-717X-8-244 | - |
dc.identifier.scopusid | 2-s2.0-84885567463 | - |
dc.identifier.wosid | 000327732500004 | - |
dc.identifier.bibliographicCitation | Radiation Oncology, v.8 | - |
dc.citation.title | Radiation Oncology | - |
dc.citation.volume | 8 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | INTRAVENOUS CONTRAST | - |
dc.subject.keywordPlus | DOSE CALCULATIONS | - |
dc.subject.keywordPlus | COMPUTED-TOMOGRAPHY | - |
dc.subject.keywordPlus | NECK-CANCER | - |
dc.subject.keywordPlus | ENHANCED CT | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | MEDIA | - |
dc.subject.keywordPlus | SCANS | - |
dc.subject.keywordPlus | LUNG | - |
dc.subject.keywordPlus | HEAD | - |
dc.subject.keywordAuthor | CyberKnife | - |
dc.subject.keywordAuthor | CT contrast | - |
dc.subject.keywordAuthor | Small field beam | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.